Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Explore the Results

Exact Sciences makes understanding Oncotype DX Colon Recurrence Score® test results as easy as possible.

Understanding Colon Recurrence Score® reports

There are 2 reports tailored to the patient’s anatomic stage: stage II MMR-P or stage III A/B.

Anatomic stage II MMR-P report

The anatomic stage II MMR-P report consists of 2 pages that include the following information:

  • Page 1 summarizes the risk of recurrence following surgery alone. You’ll see the Recurrence Score® result, along with the associated recurrence risk estimate following surgery for MMR-P patients by T stage. For patients whose Recurrence Score result is ≥41, shading in the graph indicates a higher risk
  • Page 2 shows the risk of recurrence following chemotherapy. You’ll see the patient’s Recurrence Score result, now with the associated recurrence risk estimate following 5-FU/LV alone or in combination with oxaliplatin. For patients whose Recurrence Score result is ≥41, shading in the graph indicates a higher risk

Anatomic stage III A/B report

The anatomic stage III A/B report shows risk of recurrence following chemotherapy.

  • You’ll see the patient’s Recurrence Score result with the associated recurrence risk estimate following 5-FU/LV alone or in combination with oxaliplatin
  • For patients whose Recurrence Score result is <30, shading indicates the patient is at lower risk and may be considered for 5FU/LV alone to avoid the toxicities of oxaliplatin

Use our online physician portal

Order tests, access results, receive updates, and more in one place